- Home
- CANF vs XNCR Comparison
CANF vs XNCR Comparison
Compare CANF & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- XNCR
- Stock Information
- Founded
- CANF 1994
- XNCR 1997
- Country
- CANF Israel
- XNCR United States
- Employees
- CANF N/A
- XNCR N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- XNCR Health Care
- Exchange
- CANF Nasdaq
- XNCR Nasdaq
- Market Cap
- CANF 7.9M
- XNCR N/A
- IPO Year
- CANF N/A
- XNCR 2013
- Fundamental
- Price
- CANF $1.12
- XNCR $8.79
- Analyst Decision
- CANF Strong Buy
- XNCR Buy
- Analyst Count
- CANF 2
- XNCR 9
- Target Price
- CANF $14.00
- XNCR $30.13
- AVG Volume (30 Days)
- CANF 444.9K
- XNCR 1.0M
- Earning Date
- CANF 05-20-2025
- XNCR 05-07-2025
- Dividend Yield
- CANF N/A
- XNCR N/A
- EPS Growth
- CANF N/A
- XNCR N/A
- EPS
- CANF N/A
- XNCR N/A
- Revenue
- CANF $674,000.00
- XNCR $127,228,000.00
- Revenue This Year
- CANF $461.72
- XNCR N/A
- Revenue Next Year
- CANF N/A
- XNCR $29.14
- P/E Ratio
- CANF N/A
- XNCR N/A
- Revenue Growth
- CANF N/A
- XNCR N/A
- 52 Week Low
- CANF $1.02
- XNCR $7.16
- 52 Week High
- CANF $4.69
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- CANF 40.25
- XNCR 39.10
- Support Level
- CANF $1.02
- XNCR $10.29
- Resistance Level
- CANF $1.20
- XNCR $11.70
- Average True Range (ATR)
- CANF 0.06
- XNCR 0.92
- MACD
- CANF 0.01
- XNCR -0.09
- Stochastic Oscillator
- CANF 41.30
- XNCR 20.52
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).